Optiver Holding
GLUE icon

Optiver Holding’s Monte Rosa Therapeutics GLUE Stock Holding History

Optiver Holding’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84K Sell
200
-28
-12% -$529 ﹤0.01% 2001
2026
Q1 		$3.75K Sell
228
-38
-14% -$727 ﹤0.01% 1551
2025
Q4 		$4.17K Sell
266
-318
-54% -$4.29K ﹤0.01% 1499
2025
Q3 		$4.33K Buy
+584
New +$3.09K ﹤0.01% 1863

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Optiver Holding's GLUE Position: Q2 2026 in Review

Optiver Holding reduced its Monte Rosa Therapeutics (GLUE) stake by 12% in Q2 2026, selling an estimated $529 and leaving 200 shares worth $4.84K. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Optiver Holding first reported a position in GLUE in Q3 2025 and has held it in 4 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Optiver Holding held 200 shares of Monte Rosa Therapeutics worth $4.84K as of Q2 2026.
  • Optiver Holding sold 28 Monte Rosa Therapeutics shares in Q2 2026, an estimated $529.
  • Monte Rosa Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2001 holding.
  • Optiver Holding first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.